Leptomeningeal Metastasis Clinical Trial
Official title:
A Multicenter Phase 1 Clinical Study to Determine the Maximum Tolerated Dose/Maximum Feasible Dose, Safety,& Efficacy of Single Dose Rhenium-186 NanoLiposome (186RNL) Administered Via Intraventricular Catheter for Leptomeningeal Metastases
This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).
This Phase I clinical study evaluates a single dose of 186RNL (radionuclide clinical study drug) administered through an intraventricular catheter (Ommaya reservoir) in participants with Leptomeningeal Metastases (LM). The clinical study treatment consists of a single administered 5cc dose of 186RNL per participant. The clinical study will include the evaluation at separate dose levels. Three to six participants may be treated at each dose. The maximum number of participants to be enrolled in the study is 27. The clinical study treatment will be administered, following a CSF flow study, on an outpatient basis by the clinical study physician. Participants will be followed for up to 12 months after the clinical study drug is administered. The U.S. Food and Drug Administration (FDA) has not approved 186RNL for this specific disease. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
Completed |
NCT04178343 -
Tomotherapy for Leptomeningeal Metastases
|
N/A | |
Recruiting |
NCT06399926 -
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
|
||
Not yet recruiting |
NCT06441045 -
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
|
Phase 2 | |
Recruiting |
NCT04425681 -
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
Recruiting |
NCT02803619 -
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
|
N/A | |
Recruiting |
NCT05746754 -
Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis
|
N/A | |
Not yet recruiting |
NCT04148898 -
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 2 | |
Completed |
NCT04420598 -
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
|
Phase 2 | |
Completed |
NCT02071056 -
Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
|
||
Recruiting |
NCT05385185 -
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
|
Phase 2 | |
Terminated |
NCT04729348 -
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
|
Phase 2 | |
Recruiting |
NCT06304441 -
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
|
N/A | |
Not yet recruiting |
NCT06296745 -
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
|
Phase 2 | |
Recruiting |
NCT04778800 -
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
|
N/A | |
Not yet recruiting |
NCT06282874 -
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
|
Phase 4 | |
Not yet recruiting |
NCT04356118 -
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 | |
Not yet recruiting |
NCT04356222 -
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 |